Press Releases
Draig Therapeutics to Present at the American Society for Clinical Psychopharmacology (ASCP) Annual Meeting
Draig Therapeutics to Participate in the Stifel 2026 Virtual CNS Forum
Draig Therapeutics Appoints Seasoned Neuroscience Leader Ivana Magovčević-Liebisch as President and Chief Executive Officer
Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of DT-101 for the Treatment of Major Depressive Disorder
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors
Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
Publications
ASCP Presentation: DT-101 | a Novel AMPAR PAM Demonstrating Favorable Tolerability, PK and Target Engagement in Phase 1 Healthy Volunteer Trial
ASCP Poster Presentation: DT-101 – A Novel AMPAR PAM Demonstrates Favorable Tolerability and Functional Biomarkers in Phase 1 Healthy Volunteer Trial
ASCP Poster Presentation: Magnetoencephalography (MEG) in a First-in-Human Trial toDemonstrate the Functional Consequences of Target Engagement by DT-101,a Novel AMPA Receptor Positive Allosteric Modulator
Events
The Future of Brain Health Starts Here
Whether you're a patient, caregiver, researcher, investor, or member of the press, we'd love to hear from you.
